Home › Therapeutic areas › Immunology › Rheumatoid Arthritis
Rheumatoid Arthritis (13 companies)
Companies with an active program in Rheumatoid Arthritis.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ACET | Adicet Bio | ImmunologyNeurology+2 Rare | 1 | Phase 1 | $28.6M | 8 |
| ANAB | AnaptysBio | DermatologyGI/Hepatology+2 Rare | 1 | Approved | $1.39B | 9 |
| CMMB | Chemomab Therapeutics | GI/HepatologyImmunology+1 Rare | 1 | Phase 2 | $10.6M | 4 |
| CGEM | Cullinan Therapeutics | HematologyImmunology+2 Rare | 1 | NDA Submitted | $728M | 10 |
| EVMN | Evommune | DermatologyImmunology+1 | 1 | Phase 2 | $241M | 6 |
| FATE | Fate Therapeutics | ImmunologyOncology+1 Rare | 1 | Phase 2 | $224M | 10 |
| IMVT | Immunovant | ImmunologyNeurology Rare | 1 | Phase 3 | $6.31B | 5 |
| INSM | Insmed | CardiovascularImmunology+3 Rare | 1 | Approved | $25.1B | 15 |
| JBIO | Jade Biosciences | ImmunologyRenal Rare | 1 | Phase 2 | $958M | 4 |
| KYTX | Kyverna Therapeutics | ImmunologyNeurology+1 Rare | 1 | NDA Submitted | $302M | 7 |
| NKTX | Nkarta | ImmunologyNeurology+1 Rare | 1 | Phase 1 | $124M | 8 |
| XNCR | Xencor | ImmunologyNeurology+1 Rare | 1 | Approved | $2.68B | 28 |
| ZBIO | Zenas BioPharma | DermatologyImmunology+2 Rare | 1 | NDA Submitted | $1.92B | 11 |
No companies match.